Share ownership BioArctic AB

BIOA B

SE0010323311

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 15/07/2026 pm IST			5-day change	1st Jan Change
309.60 ^SEK	-1.40%		-4.03%	-0.39%

14/07	Bioarctic: LEADER study shows more than 82 percent of Leqembi patients remained stable or improved	FW
14/07	Leqembi can now be administered at home from the start of treatment in the US	FW

Share class: BioArctic AB

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	10	1,43,99,996	0	0	48.02 %
Stock B	1	7,43,19,489	4,26,05,617 ( 57.33 %)	0

Major shareholders: BioArctic AB

Name	Stocks	%	Valuation
Lars Gunnar Lannfelt 26.25 %	1,95,11,302	26.25 %	664 M kr
Pär Lars Gellerfors 23.85 %	1,77,29,449	23.85 %	603 M kr
Fjärde AP-fonden (Investment Management) 7.29 %	54,18,493	7.29 %	184 M kr
Swedbank Robur Fonder AB 4.214 %	31,31,849	4.214 %	107 M kr
RA Capital Management LP 4.195 %	31,17,736	4.195 %	106 M kr
Nordea Investment Management AB 3.635 %	27,01,437	3.635 %	92 M kr
Unionen 3.364 %	25,00,000	3.364 %	85 M kr
Tredje AP-fonden (Investment Management) 1.607 %	11,94,212	1.607 %	41 M kr
Indecap Fonder AB 0.7037 %	5,23,007	0.7037 %	18 M kr
FCG Fonder AB 0.1685 %	1,25,223	0.1685 %	4 M kr
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
Lars Gunnar Lannfelt 60 %	86,39,998	60 %	294 M kr
Pär Lars Gellerfors 40 %	57,59,998	40 %	196 M kr

Breakdown by shareholder type

Individuals	69.83%
Institutional	22.1%
Others	3.36%
Unknown	4.71%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	69.83%
Sweden	21.12%
United States	4.19%
Netherlands	0.07%
Finland	0.06%
Australia	0.01%

Based on 1000 largest holdings

BioArctic AB is a Swedenâ€‘based biopharmaceutical company specializing in the discovery and development of diseaseâ€‘modifying treatments for neurodegenerative disorders. The Companyâ€™s primary focus is on conditions that affect the central nervous system (CNS), including Alzheimerâ€™s disease, Parkinsonâ€™s disease, and amyotrophic lateral sclerosis (ALS), areas characterized by high unmet medical need and limited effective therapies. BioArctic AB conducts advanced research and development of innovative biological drugs, with a particular emphasis on monoclonal antibodies designed to target the underlying disease mechanisms rather than only alleviating symptoms. The Company combines inâ€‘house scientific expertise with strategic collaborations with global pharmaceutical partners to advance and commercialize its therapeutic candidates worldwide.

Employees

141

Sector

Biotechnology & Medical Research

Calendar

23/07 - Earnings release - Q2 2026

More about the company